SCHEMBL12797300

SCHEMBL12797300

CN(C)/C=C1\CCCc2ccc(Br)cc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAOA P21397 2/20 0.42
▸ MAOB P27338 2/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ PARP10 Q53GL7 1/20 0.41
▸ MAPT P10636 2/20 0.38
▸ MIF P14174 2/20 0.38
▸ APP P05067 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660439 1.00 L3MBTL1 (0.48) L3MBTL1TDP1KDM4EMEN1KMT2A
SCHEMBL3660437 1.00 L3MBTL1 (0.48) L3MBTL1TDP1KDM4EMEN1KMT2A
SCHEMBL7233899 0.91 TDP1 (0.54) L3MBTL1TDP1KDM4EMEN1KMT2A
SCHEMBL31390850 0.84 KDM4E (0.62) L3MBTL1TDP1KDM4EMEN1KMT2A
SCHEMBL8431020 0.79 KDM4E (0.49) L3MBTL1TDP1KDM4EMEN1KMT2A
SCHEMBL2490099 0.79 MEN1 (0.69) L3MBTL1KDM4EMEN1KMT2AMAOA
SCHEMBL2490100 0.79 MEN1 (0.69) L3MBTL1KDM4EMEN1KMT2AMAOA
SCHEMBL23273159 0.77 CAMK2A (0.48) L3MBTL1TDP1MAOAMAOBPARP1
SCHEMBL1484983 0.75 APP (0.53) KDM4EMEN1KMT2AMAPTAPP
SCHEMBL7238871 0.75 KDM4E (0.46) KDM4EMEN1KMT2AMAOBPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 — — US disclosed
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 — — US disclosed
WO-2009089305-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 L3MBTL1 4282/4885TDP1 4423/4885KDM4E 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback